The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Open accessAbstract
Purpose: Open-label, phase III trial evaluating whether sunitinib was superior or equivalent to sorafenib in hepatocellular cancer. Patients and Methods: Patients were stratified and randomly assigned to receive sunitinib 37.5 mg once per day or sorafenib 400 mg twice per day. Primary end point was overall survival (OS). Results: Early trial termination occurred for futility and safety reasons. A total of 1,074 patients were randomly assigned to the study (sunitinib arm, n = 530; sorafenib arm, n = 544). For sunitinib and sorafenib, respectively, median OS was 7.9 versus 10.2 months (hazard ratio [HR], 1.30; one-sided P = .9990; two-sided P = .0014); median progression-free survival (PFS; 3.6 v 3.0 months; HR, 1.13; one-sided P = .8785; two-sided P = .2286) and time to progression (TTP; 4.1 v 3.8 months; HR, 1.13; one-sided P = .8312; two-sided P = .3082) were comparable. Median OS was similar among Asian (7.7 v 8.8 months; HR, 1.21; one-sided P = .9829) and hepatitis B–infected patients (7.6 v 8.0 months; HR, 1.10; one-sided P = .8286), but was shorter with sunitinib in hepatitis C–infected patients (9.2 v 17.6 months; HR, 1.52; one-sided P = .9835). Sunitinib was associated with more frequent and severe adverse events (AEs) than sorafenib. Common grade 3/4 AEs were thrombocytopenia (29.7%) and neutropenia (25.7%) for sunitinib; hand-foot syndrome (21.2%) for sorafenib. Discontinuations owing to AEs were similar (sunitinib, 13.3%; sorafenib, 12.7%). Conclusion: OS with sunitinib was not superior or equivalent but was significantly inferior to sorafenib. OS was comparable in Asian and hepatitis B–infected patients. OS was superior in hepatitis C–infected patients who received sorafenib. Sunitinib-treated patients reported more frequent and severe toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Self-citationSorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,329
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J. F., & Bell, B. P. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.05.013 · Cited by 2,572
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
O'Farrell, A.-M., Abrams, T. J., Yuen, H. A., Ngai, T. J., Louie, S. G., Yee, K. W. H., Wong, L. M., Hong, W., Lee, L. B., Town, A., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2307 · Cited by 864
Makinen, T. (2001) · The EMBO Journal · doi:10.1093/emboj/20.17.4762 · Cited by 845
Bruix, J., Raoul, J.-L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., Galle, P. R., Santoro, A., Beaugrand, M., Sangiovanni, A., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.014 · Cited by 822
Molecular basis for sunitinib efficacy and future clinical development
Faivre, S., Demetri, G., Sargent, W., & Raymond, E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2380 · Cited by 721
Self-citationAbrams, T. J., Lee, L. B., Murray, L. J., Pryer, N., & Cherrington, J. M. (2003) · PubMed · Cited by 685
(2000) · Hepatology · doi:10.1053/he.2000.5628 · Cited by 521
Zhu, A. X., Sahani, D. V., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Catalano, O. A., Sindhwani, V., Blaszkowsky, L. S., Yoon, S. S., Lahdenranta, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9908 · Cited by 477
Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis
Kwiatkowski, D. J. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.5.446 · Cited by 387
George, S., Blay, J. Y., Casali, P. G., Le Cesne, A., Stephenson, P., DePrimo, S. E., Harmon, C. S., Law, C. N. J., Morgan, J. A., Ray-Coquard, I., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.02.011 · Cited by 373
Ito, Y., Sasaki, Y., Horimoto, M., Wada, S., Tanaka, Y., Kasahara, A., Ueki, T., Hirano, T., Yamamoto, H., Fujimoto, J., et al. (1998) · Hepatology · doi:10.1002/hep.510270409 · Cited by 334
Schmitz, K. J., Wohlschlaeger, J., Lang, H., Sotiropoulos, G. C., Malago, M., Steveling, K., Reis, H., Cicinnati, V. R., Schmid, K. W., & Baba, H. A. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.08.018 · Cited by 309
Murray, L. J., Abrams, T. J., Long, K. R., Ngai, T. J., Olson, L. M., Hong, W., Keast, P. K., Brassard, J. A., O'Farrell, A. M., Cherrington, J. M., et al. (2003) · Clinical & Experimental Metastasis · doi:10.1023/b:clin.0000006873.65590.68 · Cited by 305
伊藤, 善. (1998) · doi:10.11501/3155565 · Cited by 300
Faivre, S., Raymond, E., Boucher, E., Douillard, J., Lim, H. Y., Kim, J. S., Zappa, M., Lanzalone, S., Lin, X., DePrimo, S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70171-8 · Cited by 290
Self-citationPoon, R. T.-P., Ng, I. O.-L., Lau, C., Yu, W.-C., Yang, Z.-F., Fan, S.-T., & Wong, J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.089 · Cited by 285
Je, Y., Schutz, F. A., & Choueiri, T. K. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70222-0 · Cited by 280
Kim, D. W., Jo, Y. S., Jung, H. S., Chung, H. K., Song, J. H., Park, K. C., Park, S. H., Hwang, J. H., Rha, S. Y., Kweon, G. R., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2845 · Cited by 279
Self-citationIncreased MAPK Expression and Activity in Primary Human Hepatocellular Carcinoma
Schmidt, C. M., McKillop, I. H., Cahill, P. A., & Sitzmann, J. V. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6840 · Cited by 212
Escudier, B., Roigas, J., Gillessen, S., Harmenberg, U., Srinivas, S., Mulder, S. F., Fountzilas, G., Peschel, C., Flodgren, P., Maneval, E. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5476 · Cited by 208
Tai, W.-T., Cheng, A.-L., Shiau, C.-W., Huang, H.-P., Huang, J.-W., Chen, P.-J., & Chen, K.-F. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.01.047 · Cited by 158
Self-citationGiambartolomei, S., Covone, F., Levrero, M., & Balsano, C. (2001) · Oncogene · doi:10.1038/sj.onc.1204372 · Cited by 133
Yao, D., Wu, X., Zhu, Y. M., Shi, G.-S., Dong, Z., Yao, D.-B., Wu, W., Qiu, L., & Meng, X. (2005) · PubMed · Cited by 128
Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC).
Cheng, A., Kang, Y., Lin, D., Park, J., Kudo, M., Qin, S., Omata, M., Lowenthal, S. W. P., Lanzalone, S., Yang, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.4000 · Cited by 118
Self-citationKodera, Y., Katanasaka, Y., Kitamura, Y., Tsuda, H., Nishio, K., Tamura, T., & Koizumi, F. (2011) · Breast Cancer Research · doi:10.1186/bcr2903 · Cited by 107
Koeberle, D., Montemurro, M., Samaras, P., Majno, P. E., Simcock, M., Limacher, A., Lerch, S., Kovács, K. J., Inauen, R. I., Hess, V., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0316 · Cited by 92
New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication
Himmelsbach, K., Sauter, D., Baumert, T. F., Ludwig, L., Blum, H. E., & Hildt, E. (2009) · Gut · doi:10.1136/gut.2009.182212 · Cited by 87
Zhang, Z., Liu, Z.-S., & Sun, Q. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i26.4241 · Cited by 80
Ou, D., Shen, Y., Yu, S., Chen, K., Yeh, P.-Y., Fan, H., Feng, W.-C., Wang, C.-T., Lin, L., Hsu, C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1033 · Cited by 75
Self-citationSteatosis and hepatocellular carcinoma risk.
Smedile, A., & Bugianesi, E. (2006) · PubMed · Cited by 71
Randomized Clinical Trial Design for Assessing Noninferiority When Superiority Is Expected
Freidlin, B., Korn, E. L., George, S. L., & Gray, R. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8711 · Cited by 71
Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf
Chen, K., Tai, W., Huang, J., Hsu, C.-Y., Chen, W., Cheng, A., Chen, P., & Shiau, C. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.04.007 · Cited by 34
Self-citation
Cited by
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Self-citationKudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Self-citationForner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
Metadata
- Authors
- Cheng, A.-L., Kang, Y.-K., Lin, D.-Y., Park, J.-W., Kudo, M., Qin, S., Chung, H.-C., Song, X., Xu, J., Poggi, G., Omata, M., Pitman Lowenthal, S., Lanzalone, S., Yang, L., Lechuga, M. J., & Raymond, E.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-11-10
- Volume
- 31
- Issue
- 32
- Pages
- 4067-4075
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2119242310
- Cited by
- 777
- References
- 46
- FWCI
- 38.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.